Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|November 2, 2003
- Pharmaceutical Technology-11-02-2003
- Volume 27
- Issue 11
Routine Sample Size for a Retest Procedure
Author(s)Jeffrey D. Hofer
This article discusses a straightforward approach that scientists may use to descide how many nonsuspect restest results are required to provide sufficient evidence to overcome an initial suspect result.
Advertisement
Articles in this issue
almost 23 years ago
FDA Will Drive Changes for Contract Businessalmost 23 years ago
In the Spotlight--Decemberalmost 23 years ago
Novemember 2003almost 23 years ago
FDA Seeks Risk-Based Inspection Programalmost 23 years ago
November 2003almost 23 years ago
Clearing Regulatory Hurdlesalmost 23 years ago
Improving Protein Capture for Transgenic Drug ProcessingAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement